Chronic Lymphocytic Leukemia
July 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Authors:Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Du K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M
Institution:From Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf, University Hospital Cologne and University of Cologne (K.F., O.A.-S., J.B., A.-M.F., S. Robrecht, B.E., K.-A.K., M.H.), the Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital (V.G.), CECAD (Center of Excellence on Cellular Stress Responses in Aging-Associated Diseases) (M.H.), Center for Molecular Medicine Cologne (M.H.), Cologne, Department III of Internal Medicine, University Hospital Rostock, Rostock (S.B.), Department III of Internal Medicine, Ulm University, Ulm (E.T., S.S.), the Departments of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases, and Tropical Medicine, Klinikum Schwabing, Munich (C.-M.W.), Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel (M.R.), and the Department of Hematology, Oncology, and Rheumatology, Saarland University Medical School, Homburg (S.S.) - all in Germany; Roche Products, Welwyn Garden City, United Kingdom (M.T., M.D., S.W., K.H.); Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod, Russia (O.S.); the Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy (A.M.L.); the Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (J.P.-I.); the Haematology Department, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia (S.O.); First Internal Department, Multiprofile Hospital for Active Treatment Hristo Botev, Vratsa, Bulgaria (L.S.); the Hematology Department, Clinique Victor Hugo, Le Mans, France (K.L.D.); Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil (L.M.F.); the Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen (C.U.N.); Wellington Blood and Cancer Centre, Capital and Coast District Health Board, and Malaghan Institute of Medical Research, Wellington, New Zealand (R.W.); Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada (S. Robinson); Moores Cancer Center, University of California San Diego, San Diego (T.J.K.), and Genentech, South San Francisco (M.M.) - both in California; AbbVie, North Chicago, IL (R.H.); and the Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, the Netherlands (A.W.L.).
Journal:N Engl J Med. 2019 Jun 6;380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4.

2:Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Authors:Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W
Institution:From the Departments of Leukemia (N.J., M. Keating, P.T., A.F., J.B., G.B., K.T., Z.E., T.K., M. Konopleva, Y.A., M.Y., C.D., P.B., M.O., N.P., E.J., K. Sasaki, K. Sondermann, N.C., C.W., A.A., H.K., W.W.), Lymphoma and Myeloma (N.F.), Hematopathology (R.K.-S., K.P., J.J.), Diagnostic Radiology (N.G.), Biostatistics (X.W.), and Experimental Therapeutics (W.P., V.G.), University of Texas M.D. Anderson Cancer Center, Houston.
Journal:N Engl J Med. 2019 May 30;380(22):2095-2103. doi: 10.1056/NEJMoa1900574.

3:Venetoclax in the treatment of chronic lymphocytic leukemia.
Authors:Korycka-Wolowiec A, Wolowiec D, Kubiak-Mlonka A, Robak T
Institution:a Department of Hematology , Medical University of Lodz , Lodz , Poland.
Journal:Expert Opin Drug Metab Toxicol. 2019 May;15(5):353-366. doi: 10.1080/17425255.2019.1606211. Epub 2019 Apr 25.

4:Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
Authors:Helbig G, Spalek A, Wieczorkiewicz-Kabut A, Markiewicz M, Kopera M, Zielinska P, Wozniczka K, Kopinska A, Grygoruk-Wisniowska I, Koclega A
Institution:School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dabrowski street 25, 40-032, Katowice, Poland. ghelbig@o2.pl.
Journal:Ann Hematol. 2019 Jun;98(6):1477-1483. doi: 10.1007/s00277-019-03679-x. Epub 2019 Mar 27.

5:Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience.
Authors:Herishanu Y, Tadmor T, Braester A, Bairey O, Aviv A, Rahimi-Levene N, Fineman R, Levi I, Yuklea M, Ruchlemer R, Shvidel L, Polliack A
Institution:Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. Galilee, Nahariya, Israel. University, Beer Sheba, Israel. Medical School, Jerusalem, Israel.
Journal:Hematol Oncol. 2019 Apr;37(2):185-192. doi: 10.1002/hon.2580. Epub 2019 Mar 12.

6:Relevance of TP53 for CLL diagnostics.
Authors:Catherwood MA, Gonzalez D, Donaldson D, Clifford R, Mills K, Thornton P
Institution:Haematology Department, Belfast Health and Social Care Trust, Belfast, UK mark.catherwood@belfasttrust.hscni.net. Belfast, UK. Belfast, UK.
Journal:J Clin Pathol. 2019 May;72(5):343-346. doi: 10.1136/jclinpath-2018-205622. Epub 2019 Feb 2.

7:Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Authors:Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigon MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yagci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W
Institution:Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: younesa@mskcc.org. Barcelona, Spain. Red Cancer (CIBERONC), Barcelona, Spain. Jerusalem, Israel. University, Tel Aviv, Israel. Barcelona, Spain. Brisbane, QLD, Australia.
Journal:Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

8:Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Authors:Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR
Institution:Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: matthew_davids@dfci.harvard.edu. Institute, Boston, MA, USA. USA.
Journal:Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.

9:Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
Authors:Andersen MA, Moser CE, Lundgren J, Niemann CU
Institution:Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Hospital, Copenhagen, Denmark. Denmark. Hospital, Copenhagen, Denmark. Copenhagen, Denmark. Carsten.utoft.niemann@regionh.dk.
Journal:Leukemia. 2019 Mar;33(3):662-670. doi: 10.1038/s41375-018-0316-5. Epub 2018 Dec 13.

10:Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study).
Authors:Szasz R, Altai E, Pal K, Dombi P, Ivanyi J, Jakucs J, Joni N, Illes A, Tarkanyi I, Szerafin L, Nagy Z, Farkas P, Nagy A, Piukovics K, Ujj G, Schneider T
Institution:Division of Hematology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, Debrecen, 4032, Hungary. szaszr@med.unideb.hu.; Veszprem County Csolnoky Ferenc Hospital, Korhaz u. 1, Veszprem, 8200, Hungary.; Fejer County Szent Gyorgy Hospital, Seregelyesi ut 3, Szekesfehervar, 8000, Hungary.; Department of Hematology, Szent Borbala Hospital, Dozsa Gyorgy ut 77, Tatabanya, 2800, Hungary.; Department of Hematology, Vas County Markusovszky Hospital, Markusovszky L. u. 5, Szombathely, 9700, Hungary.
Journal:Pathol Oncol Res. 2019 Apr;25(2):535-540. doi: 10.1007/s12253-018-0474-9. Epub 2018 Oct 25.

11:Measurement of Leukemic B-Cell Growth Kinetics in Patients with Chronic Lymphocytic Leukemia.
Authors:Mazzarello AN, Fitch M, Hellerstein MK, Chiorazzi N
Institution:The Feinstein Institute for Medical Research, Manhasset, NY, USA. Berkeley, Berkeley, CA, USA. Berkeley, Berkeley, CA, USA. at San Francisco, San Francisco, CA, USA. NChizzi@Northwell.edu. Hofstra/Northwell, Hempstead, NY, USA. NChizzi@Northwell.edu. Hofstra/Northwell, Hempstead, NY, USA. NChizzi@Northwell.edu.
Journal:Methods Mol Biol. 2019;1881:129-151. doi: 10.1007/978-1-4939-8876-1_11.

12:Comparative assessment of prognostic models in chronic lymphocytic leukemia: evaluation in Indian cohort.
Authors:Rani L, Gogia A, Singh V, Kumar L, Sharma A, Kaur G, Gupta R
Institution:Laboratory Oncology Unit, Dr. B.R.A.IRCH, All India Institute of Medical Sciences, New Delhi, India. Sciences, New Delhi, India. India. Sciences, New Delhi, India. Sciences, New Delhi, India. Sciences, New Delhi, India.
Journal:Ann Hematol. 2019 Feb;98(2):437-443. doi: 10.1007/s00277-018-3525-0. Epub 2018 Oct 18.

13:Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.
Authors:Manso BA, Zhang H, Mikkelson MG, Gwin KA, Secreto CR, Ding W, Parikh SA, Kay NE, Medina KL
Institution:Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, 55905, USA. Medina.Kay@mayo.edu.
Journal:Leukemia. 2019 Mar;33(3):638-652. doi: 10.1038/s41375-018-0280-0. Epub 2018 Oct 5.

14:Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.
Authors:Cuneo A, Barosi G, Danesi R, Fagiuoli S, Ghia P, Marzano A, Montillo M, Poletti V, Viale P, Zinzani PL
Institution:Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy. Experimental Medicine, University of Pisa, Pisa, Italy. Bergamo, Italy. Milan, Italy. Torino, Turin, Italy. Italy. Denmark. Studiorum - University of Bologna, Bologna, Italy. Bologna, Italy.
Journal:Hematol Oncol. 2019 Feb;37(1):3-14. doi: 10.1002/hon.2540. Epub 2018 Sep 5.

15:Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Authors:Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hullein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Durig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP
Institution:Department of Hematology and Lymphoma and Myeloma Center Amsterdam, Academic Medical Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands. Immunity Institute of Amsterdam, Amsterdam, The Netherlands.
Journal:Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: July 3, 2019
213 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL73437015

Coupon Expires: August 21, 2019



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published by Medifocus, Inc.
3809 Clarks Lane, Suite 100, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.